Hohmann, A. F., Vakoc, C. R. (June 2014) A rationale to target the SWI/SNF complex for cancer therapy. Trends in Genetics, 30 (8). pp. 356-363. ISSN 01689525
Abstract
SWI/SNF is a multisubunit chromatin-remodeling complex that performs fundamental roles in gene regulation, cell lineage specification, and organismal development. Mutations that inactivate SWI/SNF subunits are found in nearly 20% of human cancers, which indicates that the proper functioning of this complex is necessary to prevent tumor formation in diverse tissues. Recent studies show that SWI/SNF-mutant cancers depend on residual SWI/SNF complexes for their aberrant growth, thus revealing synthetic lethal interactions that could be exploited for therapeutic purposes. Other studies reveal that certain acute leukemias and small cell lung cancers, which lack SWI/SNF mutations, can be vulnerable to inhibition of the SWI/SNF ATPase subunit BRG1, whereas several normal and malignant cell types do not show this sensitivity. Here, we review the emerging evidence that implicates SWI/SNF as a tumor-dependency and candidate drug target in human cancer. © 2014 Elsevier Ltd. All rights reserved.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | cancer therapy SWI/SNF synthetic lethality |
| Subjects: | diseases & disorders > cancer diseases & disorders > cancer > drugs and therapies |
| CSHL Authors: | |
| Communities: | CSHL labs > Vakoc lab School of Biological Sciences > Publications |
| Depositing User: | Matt Covey |
| Date: | 20 June 2014 |
| Date Deposited: | 13 Jun 2014 16:06 |
| Last Modified: | 17 Apr 2015 14:28 |
| PMCID: | PMC4024079 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/30300 |
Actions (login required)
 |
Administrator's edit/view item |
